Literature DB >> 7687056

Tumor-suppressor genes: news about the interferon connection.

P Lengyel1.   

Abstract

The interferons are a family of secreted, multifunctional proteins which are components of the defenses of vertebrates against viral, bacterial, and parasitic infections and certain tumors. They exert their various activities by inducing the synthesis of a large variety of proteins. There are direct and indirect indications that several of these proteins may have tumor-suppressor activities. The interferon-inducible proteins implicated include: (i) a double-stranded RNA-activatable protein kinase that can phosphorylate and thereby inactivate the eukaryotic peptide chain initiation factor eIF-2; (ii) the interferon regulatory factors IRF-1 and IRF-2, which can modulate the expression of the interferons and of some interferon-inducible proteins; and (iii) RNase L, a latent endoribonuclease which can be activated by (2'-5')oligoadenylates, the products of a family of enzymes which are also interferon-inducible. It is note-worthy that some of the proteins encoded by tumor virus oncogenes (e.g., E1A from adenovirus, EBNA-2 from Epstein-Barr virus, and terminal protein from hepatitis B virus) impair the induction of at least some proteins by interferons.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7687056      PMCID: PMC46832          DOI: 10.1073/pnas.90.13.5893

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.

Authors:  J I Cohen; F Wang; J Mannick; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

Review 2.  Interferons: a new class of tumor suppressor genes?

Authors:  P M Pitha
Journal:  Cancer Cells       Date:  1990-07

3.  The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells.

Authors:  S B Lee; Z Melkova; W Yan; B R Williams; A G Hovanessian; M Esteban
Journal:  Virology       Date:  1993-01       Impact factor: 3.616

4.  Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap.

Authors:  A Lazaris-Karatzas; K S Montine; N Sonenberg
Journal:  Nature       Date:  1990-06-07       Impact factor: 49.962

5.  Transcription of interferon-stimulated genes is induced by adenovirus particles but is suppressed by E1A gene products.

Authors:  N Reich; R Pine; D Levy; J E Darnell
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

6.  Adenovirus early region 1A modulation of interferon antiviral activity.

Authors:  K P Anderson; E H Fennie
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

7.  Overexpression of eukaryotic protein synthesis initiation factor 4E in HeLa cells results in aberrant growth and morphology.

Authors:  A De Benedetti; R E Rhoads
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.

Authors:  W Hammerschmidt; B Sugden
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

9.  Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways.

Authors:  T Fujita; L F Reis; N Watanabe; Y Kimura; T Taniguchi; J Vilcek
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  An Epstein-Barr virus immortalization associated gene segment interferes specifically with the IFN-induced anti-proliferative response in human B-lymphoid cell lines.

Authors:  P Aman; A von Gabain
Journal:  EMBO J       Date:  1990-01       Impact factor: 11.598

View more
  48 in total

1.  Sensitivity of an epstein-barr virus-positive tumor line, Daudi, to alpha interferon correlates with expression of a GC-rich viral transcript.

Authors:  Y Gao; S a Xue; B E Griffin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

Review 2.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

3.  Tyrosine phosphorylation acts as a molecular switch to full-scale activation of the eIF2alpha RNA-dependent protein kinase.

Authors:  Qiaozhu Su; Shuo Wang; Dionissios Baltzis; Li-Ke Qu; Andrew Hoi-Tao Wong; Antonis E Koromilas
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-22       Impact factor: 11.205

Review 4.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

5.  Differential role of Sp100 isoforms in interferon-mediated repression of herpes simplex virus type 1 immediate-early protein expression.

Authors:  Dmitri G Negorev; Olga V Vladimirova; Alexey Ivanov; Frank Rauscher; Gerd G Maul
Journal:  J Virol       Date:  2006-08       Impact factor: 5.103

6.  The 58,000-dalton cellular inhibitor of the interferon-induced double-stranded RNA-activated protein kinase (PKR) is a member of the tetratricopeptide repeat family of proteins.

Authors:  T G Lee; N Tang; S Thompson; J Miller; M G Katze
Journal:  Mol Cell Biol       Date:  1994-04       Impact factor: 4.272

7.  The interferon-inducible double-stranded RNA-activated protein kinase self-associates in vitro and in vivo.

Authors:  R C Patel; P Stanton; N M McMillan; B R Williams; G C Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

8.  PACT, a protein activator of the interferon-induced protein kinase, PKR.

Authors:  R C Patel; G C Sen
Journal:  EMBO J       Date:  1998-08-03       Impact factor: 11.598

Review 9.  Translation-targeted therapeutics for viral diseases.

Authors:  J B Harford
Journal:  Gene Expr       Date:  1995

Review 10.  Cytokine therapeutics: lessons from interferon alpha.

Authors:  J U Gutterman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.